This site is intended for U.S. Health Care Professionals.

Our products are indicated for a wide range of tumor types. Click on the product link to see more information on safety, efficacy, dosing, and full prescribing information. Please see Important Safety Information below.

BOSULIF® (bosutinib) is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.

View: BOSULIF | Prescribing information

INLYTA® (axitinib) is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

View: INLYTA | Prescribing information

SUTENT® (sunitinib malate) is indicated for the treatment of advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, and progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.

View: SUTENT | Prescribing Information, including Boxed Warning and Medication Guide
TORISEL® (temsirolimus) is indicated for the treatment of advanced renal cell carcinoma.

View: TORISEL | Prescribing information
XALKORI® (crizotinib) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

View: XALKORI | Prescribing information

BOSULIF® (bosutinib) Important Safety Information
[[nid:oncology/includes/bosulif_ISI/bosulif_ISI.html]]

Please see full Prescribing Information for BOSULIF® (bosutinib).

Indication Statement
[[nid:oncology/includes/bosulif_ISI/bosulif_indication.html]] Back to top
INLYTA® (axitinib) Important Safety Information
[[nid:oncology/includes/inlyta_ISI/inlyta_ISI.html]]

Please see full Prescribing Information for INLYTA® (axitinib).

Indication Statement
[[nid:oncology/includes/inlyta_ISI/inlyta_indication.html]] Back to top
SUTENT® (sunitinib malate) Important Safety Information
[[nid:oncology/includes/sutent_ISI/sutent_ISI.html]]

Please see full Prescribing Information, including Boxed Warning, for SUTENT® (sunitinib malate).

Indication Statement
[[nid:oncology/includes/sutent_ISI/sutent_indication.html]] Back to top
TORISEL® (temsirolimus) Important Safety Information
[[nid:oncology/includes/torisel_ISI/torisel_ISI.html]]

Please see full Prescribing Information for TORISEL® (temsirolimus) injection.

Indication Statement
[[nid:oncology/includes/torisel_ISI/torisel_indication.html]] Back to top
XALKORI® (crizotinib) Important Safety Information
[[nid:oncology/includes/xalkori_ISI/xalkori_ISI.html]]

Please see full Prescribing Information for XALKORI® (crizotinib).

Indication Statement
[[nid:oncology/includes/xalkori_ISI/xalkori_indication.html]] Back to top
CRI625907-01